<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00585611</url>
  </required_header>
  <id_info>
    <org_study_id>H-2005-0430</org_study_id>
    <nct_id>NCT00585611</nct_id>
  </id_info>
  <brief_title>Effects of Statin Therapy on Vascular Properties and Outcomes in Diastolic Heart Failure Patients</brief_title>
  <official_title>Effects of Statin Therapy on Vascular Properties and Outcomes in Diastolic Heart Failure Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Wisconsin, Madison</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Wisconsin, Madison</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study is designed to define the underlying vascular abnormalities present in patients
      with diastolic heart failure and test the effect of a therapy aimed at vascular
      abnormalities. This study is designed to investigate the effects of therapy with atorvastatin
      in subjects with diastolic heart failure to improve abnormalities of vascular and myocardial
      structure and function, with particular emphasis on arterial stiffness and endothelial
      dysfunction.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Forty subjects will be given either drug (atorvastatin 40 mg) or placebo in a randomized
      fashion once daily for six months. Using echocardiography, tonometry, and flow mediated
      dilation of conduit arteries and arterioles, baseline cardiovascular anatomy and physiology
      will be defined. Subjects that enroll in the study will be required to come in for 5 study
      visits. The initial visit is a screening visit; subject consent is obtained and an
      echocardiogram is performed as well as blood tests. At the randomization visit (4-14 days
      following screening), the subject will be provided with drug or placebo in a blinded
      fashion.Also at this visit, subjects will be asked to do a 6 minute walk, QOL questionnaire,
      and vascular function testing. There will be follow-up study visits at 1 and 3 months
      following randomization. At each follow-up visit a medical history, pill count and brief
      physical examination will be performed, a repeat QOL questionnaire administered, and blood
      tests to assess safety of the statin therapy. At 6 months, the final study visit will occur.
      At this visit a full history and detailed physical examination will be performed. Repeat
      echocardiogram, 6 minute walk test, QOL questionnaire, and vascular function examinations
      will be performed.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Unable to recruit into the study
  </why_stopped>
  <start_date>December 2005</start_date>
  <completion_date type="Actual">June 2008</completion_date>
  <primary_completion_date type="Actual">June 2008</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Carotid-femoral Pulse Wave Velocity (CFPWV) in the Statin Treated vs. Control Group</measure>
    <time_frame>6 months after initiation of intervention</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Composite Cardiovascular Endpoint Incorporating Quality of Life (QOL) Assessment + Hospitalizations for Cardiovascular Disease and Mortality</measure>
    <time_frame>6 months after initiation of intervention</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in Submaximal Exercise Capacity Measured by 6-minute Walk Test</measure>
    <time_frame>6 months after initiation of intervention</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">1</enrollment>
  <condition>Diastolic Heart Failure</condition>
  <arm_group>
    <arm_group_label>Atorvastatin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Heart failure patients assigned to atorvastatin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Atorvastatin</intervention_name>
    <description>Atorvastatin - 40 mg orally daily for 6 months</description>
    <arm_group_label>2</arm_group_label>
    <arm_group_label>Atorvastatin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>placebo</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Signed informed consent,

          -  Age &gt; 18,

          -  Ejection fraction â‰¥ 50%,

          -  hospitalization for heart failure in the last 6 months and

          -  current NYHA Class II-IV symptoms, OR

          -  current NYHA Class III-IV symptoms and one of the following:

               1. ECG or echocardiographic evidence of moderate/severe left ventricular
                  hypertrophy,

               2. chest x-ray evidence of pulmonary congestion

        Exclusion Criteria:

          -  Probable alternative cause of symptoms (pulmonary disease, severe anemia, etc.)

          -  Prior documented LVEF &lt; 40% or qualitative moderate or greater LV systolic
             dysfunction.

          -  Current indication for statin therapy

          -  Intolerance to statin therapy.

          -  Documented ischemic heart disease requiring lipid-lowering therapy (i.e. CAD,
             myocardial infarction, stroke)

          -  Evidence of significant myocardial ischemia on stress testing at screening visit.

          -  Evidence of hepatic abnormality (defined as liver enzymes &gt; 2 times the upper limit of
             normal values).

          -  Uncontrolled hypertension (BP &gt; 150/100)

          -  Significant valvular disease.

          -  Atrial fibrillation

          -  Known familial hypertrophic cardiomyopathy or obstructive hypertrophic cardiomyopathy.

          -  Restrictive cardiomyopathy or systemic illness known to be associated with
             infiltrative heart disease (i.e. amyloidosis, sarcoidosis, hemochromatosis).

          -  Cor pulmonale or other cause of right heart failure not related to LV dysfunction.

          -  Clinically significant pulmonary disease.

          -  Pericardial constriction or hemodynamically significant pleural effusion.

          -  Uncontrolled arrhythmia.

          -  Any systemic condition other than heart failure that may limit survival to less than 2
             years.

          -  Advance renal disease (serum creatinine &gt; 3.0 mg/dl or on dialysis)

          -  Known intolerance or allergy to HMG CoA reductase inhibitors

          -  Uncontrolled hyper- or hypothyroidism.

          -  Any subject characteristic that may interfere with study compliance, such as baseline
             dementia, substance abuse, history of non-compliance with medications or appointments.

          -  Prisoners or other vulnerable populations.

          -  Any woman of child-bearing age with a documented positive pregnancy test.

          -  Subject is receiving therapy with other investigational therapy or is participating in
             any other clinical trial.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nancy K Sweitzer, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Wisconsin, Madison</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Wisconsin Hospital and Clinics</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53792</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2019</verification_date>
  <study_first_submitted>December 26, 2007</study_first_submitted>
  <study_first_submitted_qc>January 2, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 3, 2008</study_first_posted>
  <results_first_submitted>March 6, 2019</results_first_submitted>
  <results_first_submitted_qc>March 6, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">March 26, 2019</results_first_posted>
  <last_update_submitted>March 6, 2019</last_update_submitted>
  <last_update_submitted_qc>March 6, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">March 26, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Heart Failure, Congestive</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
    <mesh_term>Heart Failure, Diastolic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atorvastatin</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>While the record documents 1 participant enrolled in this study, there are no data available to report.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Atorvastatin</title>
          <description>Heart failure patients assigned to atorvastatin
Atorvastatin: Atorvastatin - 40 mg orally daily for 6 months</description>
        </group>
        <group group_id="P2">
          <title>Arm 2</title>
          <description>Atorvastatin: Atorvastatin - 40 mg orally daily for 6 months
placebo: placebo</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>There are no data available</population>
      <group_list>
        <group group_id="B1">
          <title>Atorvastatin</title>
          <description>Heart failure patients assigned to atorvastatin
Atorvastatin: Atorvastatin - 40 mg orally daily for 6 months</description>
        </group>
        <group group_id="B2">
          <title>Arm 2</title>
          <description>Atorvastatin: Atorvastatin - 40 mg orally daily for 6 months
placebo: placebo</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="0"/>
            <count group_id="B2" value="0"/>
            <count group_id="B3" value="0"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                </category>
                <category>
                  <title>Male</title>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race and Ethnicity Not Collected</title>
          <population>Race and Ethnicity were not collected from any participant.</population>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <class_list>
            <class>
              <title>United States</title>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Carotid-femoral Pulse Wave Velocity (CFPWV) in the Statin Treated vs. Control Group</title>
        <time_frame>6 months after initiation of intervention</time_frame>
        <population>There are no data available</population>
        <group_list>
          <group group_id="O1">
            <title>Atorvastatin</title>
            <description>Heart failure patients assigned to atorvastatin
Atorvastatin: Atorvastatin - 40 mg orally daily for 6 months</description>
          </group>
          <group group_id="O2">
            <title>Arm 2</title>
            <description>Atorvastatin: Atorvastatin - 40 mg orally daily for 6 months
placebo: placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Carotid-femoral Pulse Wave Velocity (CFPWV) in the Statin Treated vs. Control Group</title>
          <population>There are no data available</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Composite Cardiovascular Endpoint Incorporating Quality of Life (QOL) Assessment + Hospitalizations for Cardiovascular Disease and Mortality</title>
        <time_frame>6 months after initiation of intervention</time_frame>
        <population>There are no data available.</population>
        <group_list>
          <group group_id="O1">
            <title>Atorvastatin</title>
            <description>Heart failure patients assigned to atorvastatin
Atorvastatin: Atorvastatin - 40 mg orally daily for 6 months</description>
          </group>
          <group group_id="O2">
            <title>Arm 2</title>
            <description>Atorvastatin: Atorvastatin - 40 mg orally daily for 6 months
placebo: placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Composite Cardiovascular Endpoint Incorporating Quality of Life (QOL) Assessment + Hospitalizations for Cardiovascular Disease and Mortality</title>
          <population>There are no data available.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Changes in Submaximal Exercise Capacity Measured by 6-minute Walk Test</title>
        <time_frame>6 months after initiation of intervention</time_frame>
        <population>There are no data available.</population>
        <group_list>
          <group group_id="O1">
            <title>Atorvastatin</title>
            <description>Heart failure patients assigned to atorvastatin
Atorvastatin: Atorvastatin - 40 mg orally daily for 6 months</description>
          </group>
          <group group_id="O2">
            <title>Arm 2</title>
            <description>Atorvastatin: Atorvastatin - 40 mg orally daily for 6 months
placebo: placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Changes in Submaximal Exercise Capacity Measured by 6-minute Walk Test</title>
          <population>There are no data available.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>There are no data available</time_frame>
      <desc>There are no data available to report.</desc>
      <group_list>
        <group group_id="E1">
          <title>Atorvastatin</title>
          <description>Heart failure patients assigned to atorvastatin
Atorvastatin: Atorvastatin - 40 mg orally daily for 6 months</description>
        </group>
        <group group_id="E2">
          <title>Arm 2</title>
          <description>Atorvastatin: Atorvastatin - 40 mg orally daily for 6 months
placebo: placebo</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>PI left UW-Madison, has no data for participant enrolled.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Nancy Sweitzer</name_or_title>
      <organization>UW-Madison at time of study</organization>
      <email>nancysweitzer@shc.arizona.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

